| Description | Thalidomide-O-amido-PEG4-propargyl is a polyethylene glycol (PEG)-based linker employed for the synthesis of proteolysis targeting chimeras (PROTACs)[1]. |
| In vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. |
| molecular weight | 545.54 |
| Molecular formula | C26H31N3O10 |
| CAS | T18823 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
Thalidomide-O-amido-PEG4-propargyl
CAS No.: T18823
Thalidomide-O-amido-PEG4-propargyl is a polyethylene glycol (PEG)-based linker employed for the synthesis of proteolysis
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.